Skip to main
FGEN
FGEN logo

FibroGen (FGEN) Stock Forecast & Price Target

FibroGen (FGEN) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 31%
Hold 38%
Sell 8%
Strong Sell 8%

Bulls say

FibroGen Inc. is positioned favorably in the biotechnology sector, with promising potential for product candidates such as FG-3246 that may outperform existing standard of care therapies in clinical trials. The company's financial structure is enhanced by the revenue stream from roxadustat, which mitigates reliance on dilutive capital raises, and is further supported by a solid cash reserve of $51 million, not including an anticipated $75 million from the pending sale of FibroGen China to AstraZeneca. This financial stability, along with the strategic regaining of development rights for key therapeutics, underscores a strong outlook for FibroGen as it navigates macroeconomic challenges while advancing its research and development initiatives.

Bears say

FibroGen Inc faces significant risks that could adversely impact its financial outlook, primarily due to the potential for failed or inconclusive clinical trials which would hinder its product development. Additionally, the company may struggle to secure adequate funding necessary to advance its therapeutics, raising concerns about possible dilutive capital raises that could weaken shareholder value. The lack of commercial success and the associated delisting risk further compound these challenges, creating a pessimistic scenario for the company’s financial stability and future growth.

FibroGen (FGEN) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 31% recommend Buy, 38% suggest Holding, 8% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of FibroGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About FibroGen (FGEN) Forecast

Analysts have given FibroGen (FGEN) a Hold based on their latest research and market trends.

According to 13 analysts, FibroGen (FGEN) has a Hold consensus rating as of Sep 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

FibroGen (FGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.